Which neuroscience drugs go off patent, and when?
5 blockbuster neuroscience drugs with about $24.4B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Ocrevus (Roche, $8.4B). The biggest single year is 2029, with $12.1B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Ocrevus | Roche | 2029 | ≈$8.4B | Patent-expiry estimate | In clinical trials | – |
| Vraylar | AbbVie | 2029 | $3.6B | Patent-expiry estimate | Approved, waiting to launch | 2027 · −44% |
| Kesimpta | Novartis | 2031 | $4.4B | Company guidance | Early development | – |
| Invega Sustenna | Johnson & Johnson | 2031 | $3.8B | Patent-expiry estimate | Filed with the FDA | – |
| Vyvgart | argenx | 2036 | $4.2B | Patent-expiry estimate | No US filing found | – |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Roche | Ocrevus | ≈$8.4B | 11% |
| Novartis | Kesimpta | $4.4B | 8.1% |
| argenx | Vyvgart | $4.2B | 98% |
| Johnson & Johnson | Invega Sustenna | $3.8B | 4% |
| AbbVie | Vraylar | $3.6B | 5.9% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Vraylar (2027, −44%) was selected for Medicare price negotiation. See every negotiated Medicare price →